Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Converging Crises of Extreme Heat and Homelessness.

JAMA internal medicine·2025
Same author

HPV Self-Collection for Cervical Cancer Screening-There's No Place Like Home.

JAMA internal medicine·2025
Same author

Joint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States.

Circulation·2025
Same author

Temporal Trends in Opioid Use and Associated Outcomes for Patients Living with Advanced Cancer.

Journal of pain and symptom management·2025
Same author

Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional study.

Clinical trials (London, England)·2025
Same author

Salary Differences by Gender, Race, and Ethnicity Among Assistant Professors at US Medical Schools.

JAMA network open·2025

Related Experiment Video

Updated: May 27, 2026

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Promoting transparency in pharmaceutical industry-sponsored research.

Joseph S Ross1, Cary P Gross, Harlan M Krumholz

  • 1Section of General Internal Medicine, Yale University School of Medicine and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT 06520-8093, USA. joseph.ross@yale.edu

American Journal of Public Health
|November 19, 2011
PubMed
Summary

Industry practices can distort medical research, impacting patient care. Promoting transparency in clinical trials through disclosure and public registration is crucial for safeguarding medical literature integrity and public health.

More Related Videos

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

Related Experiment Videos

Last Updated: May 27, 2026

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

Area of Science:

  • Medical research integrity
  • Clinical trial transparency
  • Evidence-based practice

Background:

  • Objective research is vital for clinical decisions and guidelines.
  • Industry employs tactics like ghostwriting and selective reporting to manipulate medical literature.
  • These practices obscure critical information for patients and physicians.

Purpose of the Study:

  • To identify industry practices that distort medical literature.
  • To propose policy solutions for enhancing transparency in clinical trial research.
  • To protect the integrity of medical literature and public health.

Main Methods:

  • Analysis of industry tactics used to influence clinical trial outcomes.
  • Review of current policies related to clinical trial disclosure and registration.
  • Examination of the impact of marketing on medical research.

Main Results:

  • Industry uses seeding trials, publication planning, and ghostwriting to bias research.
  • Selective publication and reporting of outcomes obscure vital data.
  • Lack of transparency undermines evidence-based practice.

Conclusions:

  • Policies promoting transparency, including expanded disclosure and public registration, are essential.
  • Independent analysis of clinical trial data can improve accountability.
  • Minimizing marketing's influence and strengthening scientific rigor are key to protecting public health.